BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
10/29/2014 7:34:00 PM | Browse: 1104 | Download: 1538
 |
Received |
|
2014-03-26 09:32 |
 |
Peer-Review Started |
|
2014-03-26 21:12 |
 |
To Make the First Decision |
|
2014-04-28 14:14 |
 |
Return for Revision |
|
2014-05-03 19:34 |
 |
Revised |
|
2014-05-14 20:34 |
 |
Second Decision |
|
2014-07-16 17:11 |
 |
Accepted by Journal Editor-in-Chief |
|
|
 |
Accepted by Executive Editor-in-Chief |
|
2014-07-16 17:31 |
 |
Articles in Press |
|
2014-07-16 17:49 |
 |
Publication Fee Transferred |
|
|
 |
Edit the Manuscript by Language Editor |
|
2014-07-28 16:35 |
 |
Typeset the Manuscript |
|
2014-10-15 20:00 |
 |
Publish the Manuscript Online |
|
2014-10-29 19:34 |
Category |
Endocrinology & Metabolism |
Manuscript Type |
Review |
Article Title |
Effects of glucagon-like peptide-1 receptor agonists on non-alcoholic fatty liver disease and inflammation
|
Manuscript Source |
Unsolicited Manuscript |
All Author List |
Xing-Chun Wang, Aaron M Gusdon, Huan Liu and Shen Qu |
Funding Agency and Grant Number |
|
Corresponding Author |
Shen Qu, Professor, Department of Endocrinology and Metabolism, Shanghai 10th People’s Hospital, Tongji University, 301 Middle Yanchang Road, Shanghai 200072, China. qushencn@hotmail.com |
Key Words |
Glucagon-like peptide-1 receptor agonists; Liver function; Fat content; Non-alcoholic fatty liver disease; Inflammation |
Core Tip |
The findings showed that glucagon-like peptide-1 receptor agonists (GLP-1RAs) may improve liver function, fat content and distribution, lipid metabolism and reduce the activity of inflammatory cytokines and their associated signal transduction pathways. Thus, we review here that GLP-1RAs are a potential method for pharmacologic treatment that can benefit patients with non-alcoholic fatty liver disease and chronic inflammation. |
Publish Date |
2014-10-29 19:34 |
Citation |
Wang XC, Gusdon AM, Liu H, Qu S. Effects of glucagon-like peptide-1 receptor agonists on non-alcoholic fatty liver disease and inflammation. World J Gastroenterol 2014; 20(40): 14821-14830 |
URL |
http://www.wjgnet.com/1007-9327/full/v20/i40/14821.htm |
DOI |
http://dx.doi.org/10.3748/wjg.v20.i40.14821 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345